Sanofi

We chase the miracles of science so you can chase your dreams.

Discover more

People Stories

We’re proud to spotlight those who inspire us to keep going further in the work we do.

A woman wearing a black wetsuit holds a surfboard under blue skies and sunshine while looking out to the horizon with a hopeful and determined expression.​

Céline, living with secondary progressive multiple sclerosis

France

Two women in black wetsuits standing on a beach with a surfboard, ready for surfing

The Power of Chasing A Dream

Every day, we chase the miracles of science to improve people’s lives. We apply our deep understanding of the immune system to develop breakthrough innovations in medicines and vaccines so you can focus on what matters most, chasing your dreams. If you’re chasing your dreams, remember... you’re not alone. We’re right beside you. 

 


Our Latest Articles

Two women and a man in a modern office space in a meeting.

Our Science

January 6, 2026

Our Human-Centric Approach to Partnership Amidst an Evolving Biotech Landscape

We are an R&D driven, AI-powered biopharmaceutical company committed to improving people’s lives and delivering compelling growth

About Us

Who We Are

We are an R&D driven,
AI-powered biopharma company committed to improving people’s lives and creating compelling growth.

Our Pipeline

5

Therapeutic areas

93

Compounds in clinical development

26

Clinical trials in phase 3

Pursue Progress. Discover Extraordinary. 

Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.

Our Latest Press Releases


January 5, 2026
Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes

December 24, 2025
Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

December 24, 2025
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

December 23, 2025
Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia